Clinical Trial

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg/m\^2).
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-10
Trial Details
NCT Number NCT07626515
Lead Sponsor Hoffmann-La Roche
Conditions Healthy Participants
Enrollment 36 participants
Start Date 2026-07-02
Primary Completion 2027-05-14 (estimated)
Study Completion 2027-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-10